Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

Fast and accurate long-read alignment with Burrows-Wheeler transform.

Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461

Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme

Muramatsu, M., Kinoshita, K., Fagarasan, S., Yamada, S., Shinkai, Y., & Honjo, T. (2000) · Cell · doi:10.1016/s0092-8674(00)00078-7 · Cited by 3,475

Clonal evolution in cancer

Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414

Sp140 is a multi-SUMO-1 target and its PHD finger promotes SUMOylation of the adjacent Bromodomain

Zucchelli, C., Tamburri, S., Filosa, G., Ghitti, M., Quilici, G., Bachi, A., & Musco, G. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.11.011 · Cited by 14

Molecular correlates of immune cytolytic subgroups in colorectal cancer by integrated genomics analysis

Roufas, C., Georgakopoulos‐Soares, I., & Zaravinos, A. (2021) · NAR Cancer · doi:10.1093/narcan/zcab005 · Cited by 14

Phenotyping clonal populations of glioma stem cell reveals a high degree of plasticity in response to changes of microenvironment

Innes, J. A., Lowe, A., Fonseca, R., Aley, N., El-Hassan, T., Constantinou, M., Lau, J., Eddaoudi, A., Marino, S., & Brandner, S. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00695-2 · Cited by 14

Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?

Ray, U., & Orlowski, R. Z. (2023) · Pharmaceuticals · doi:10.3390/ph16040590 · Cited by 17

EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms

Goldsmith, S. R., Fiala, M. A., O’Neal, J., Souroullas, G. P., Toama, W., Vij, R., & Schroeder, M. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.08.010 · Cited by 14

Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma

Ang, D. A., Carter, J.-M., Deka, K., Tan, J. H. L., Zhou, J., Chen, Q., Chng, W. J., Harmston, N., & Li, Y. (2024) · Nature Communications · doi:10.1038/s41467-024-46728-4 · Cited by 13

Ultra-precise detection of mutations by droplet-based amplification of circularized DNA

Wang, K., Ma, Q., Jiang, L., Lai, S., Lu, X., Hou, Y., Wu, C., & Ruan, J. (2016) · BMC Genomics · doi:10.1186/s12864-016-2480-1 · Cited by 13

Towards Stratified Medicine in Plasma Cell Myeloma

Egan, P. A., Drain, S., Conway, C., Bjourson, A. J., & Alexander, H. R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101760 · Cited by 13

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma

Adamia, S., Abiatari, I., Amin, S. B., Fulciniti, M., Minvielle, S., Cheng, L., Moreau, P., Avet‐Loiseau, H., Munshi, N. C., & Anderson, K. C. (2019) · Leukemia · doi:10.1038/s41375-019-0498-5 · Cited by 13

Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways

Saadoune, C., Nouadi, B., Hamdaoui, H., Chegdani, F., & Bennis, F. (2022) · Bioinformatics and Biology Insights · doi:10.1177/11779322221115545 · Cited by 13

Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma

Tsukamoto, T., Kinoshita, M., Yamada, K., Ito, H., Yamaguchi, T., Chinen, Y., Mizutani, S., Fujino, T., Kobayashi, T., Shimura, Y., et al. (2023) · Journal of Human Genetics · doi:10.1038/s10038-023-01136-2 · Cited by 13

Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138−CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis

Martello, M., Remondini, D., Borsi, E., Santacroce, B., Procacci, M., Pezzi, A., Dico, F. A., Martinelli, G., Zamagni, E., Tacchetti, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.77 · Cited by 13

Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer

Lan, Y., Zhao, E., Luo, S., Xiao, Y., Li, X., & Cheng, S. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05153-8 · Cited by 13

Culture and application of conditionally reprogrammed primary tumor cells

Zhong, M., & Fu, L. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa023 · Cited by 13

Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?

Thakral, D., Das, N., Basnal, A., & Gupta, R. (2020) · PubMed · Cited by 16

The Origins and Consequences of Localized and Global Somatic HypermutationPreprint

Yousif, F., Prokopec, S. D., Sun, R. X., Fan, F., Lalansingh, C. M., Park, D. H., Szyca, L., PCAWG Network, & Boutros, P. C. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/287839 · Cited by 13

Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells

Ramakrishnan, V., & Mager, D. E. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.247924 · Cited by 12

One-lincRNA and five-mRNA based signature for prognosis of multiple myeloma patients undergoing proteasome inhibitors therapy

Liu, Y., Yang, N., Peng, X., Liu, G., Zhong, H., & Liu, L. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109254 · Cited by 12

Genomic profiling of multiple myeloma: New insights and modern technologies

Hultcrantz, M. L., Yellapantula, V. D., & Rustad, E. H. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101153 · Cited by 13

Somatic Genomic Mosaicism in Multiple Myeloma

Ye, C. J., Chen, J., Liu, G., & Heng, H. H. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00388 · Cited by 12

Reconstructing tumor evolutionary histories and clone trees in polynomial-time with SubMARine

Sundermann, L. K., Wintersinger, J. A., Rätsch, G., Stoye, J., & Morris, Q. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008400 · Cited by 12

Genetic Predictors of Mortality in Patients with Multiple Myeloma

Hassan, H., & Szalat, R. E. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s262866 · Cited by 12

Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma

Haertle, L., Buenache, N., Hernández, H. N. C., Šimíček, M., Šnaurová, R., Rapado, I., Martı́nez, N., López‐Muñoz, N., Sánchez‐Pina, J. M., Munawar, U., et al. (2023) · Cancers · doi:10.3390/cancers15020532 · Cited by 12

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine

Nurminen, A., Jaatinen, S., Taavitsainen, S., Högnäs, G., Lesluyes, T., Ansari‐Pour, N., Tolonen, T. T., Haase, K., Koskenalho, A., Kankainen, M., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01242-y · Cited by 12

Additional–structural–chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience

Carballo-Zarate, A. A., Medeiros, L. J., Fang, L., Shah, J. J., Weber, D. M., Thomas, S. K., Manasanch, E. E., Hao, S., Shen, Q., Orlowski, R. Z., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.3 · Cited by 12

Standardisation of minimal residual disease in multiple myeloma

Innao, V., Allegra, A., Russo, S., Gerace, D. G., Vaddinelli, D., Alonci, A., Allegra, A. G., & Musolino, C. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12732 · Cited by 12

Waldenström′s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection

Growková, K., Kryukova, E., Chyra, Z., Filipová, J., Ševčíková, T., Říhová, L., Kaščák, M., Kryukov, F., & Hájek, R. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12959 · Cited by 12

Impact of cell fusion in myeloma marrow microenvironment on tumor progression

Wang, Z., Yuan, Y., Zhang, L., Min, Z., Zhou, D., Sun, Y., Wang, P., Ju, S., Li, J., & Fu, J. (2018) · Oncotarget · doi:10.18632/oncotarget.25742 · Cited by 12

Drug Sensitivity and Drug Repurposing Platform for Cancer Precision Medicine

Nweke, E. E., & Raj, D. B. T. G. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_622 · Cited by 13

Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches

Szalat, R. E., & Munshi, N. C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159017 · Cited by 12

Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma

Offidani, M., Boccadoro, M., Raimondo, F. D., Petrucci, M. T., Tosi, P., & Cavo, M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00507-x · Cited by 12

The “Achilles' Heel” of Cancer and Its Implications for the Development of Novel Immunotherapeutic StrategiesPreprint

Joshi, K., Chain, B., Peggs, K. S., & Quezada, S. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027086 · Cited by 12

*K-Means and Cluster Models for Cancer SignaturesPreprint

Kakushadze, Z., & Yu, W. (2017) · SSRN Electronic Journal · doi:10.2139/ssrn.2908286 · Cited by 12

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma

Isa, R., Horinaka, M., Tsukamoto, T., Mizuhara, K., Fujibayashi, Y., Taminishi-Katsuragawa, Y., Okamoto, H., Yasuda, S., Kawaji-Kanayama, Y., Matsumura-Kimoto, Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062919 · Cited by 11

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

Medina-Herrera, A., Vazquez, I., Cuenca, I., Rosa-Rosa, J. M., Ariceta, B., Jimenez, C., Fernandez-Mercado, M., Larrayoz, M. J., Gutierrez, N. C., Fernandez-Guijarro, M., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01053-3 · Cited by 11

Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma

Trudu, M., Oliva, L., Orfanelli, U., Romano, A., Raimondo, F. D., Sanvito, F., Ponzoni, M., & Cenci, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968208 · Cited by 11

Mutations of ARID1B, PIK3C2B, KMT2B, and FAT1 genes influence clinical outcome in newly diagnosed myeloma

Morawska, M., Kiełbus, M., Paziewska, M., Szelest, M., Karczmarczyk, A., Zaleska, J., Własiuk, P., Giannopoulos, K., & Grząśko, N. (2024) · Cancer Genetics · doi:10.1016/j.cancergen.2024.11.001 · Cited by 11

Multiple Myeloma Insights from Single-Cell Analysis: Clonal Evolution, the Microenvironment, Therapy Evasion, and Clinical Implications

Li, S., Liu, J., Peyton, M., Lazaro, O., McCabe, S., Huang, X., Liu, Y., Shi, Z., Zhang, Z., Walker, B. A., et al. (2025) · Cancers · doi:10.3390/cancers17040653 · Cited by 11

mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives

Pati, S. S., Dhal, S., Pattnaik, R., Tripathy, S., & Kumar, S. (2025) · Current Medical Science · doi:10.1007/s11596-025-00112-5 · Cited by 11

How is patient care for multiple myeloma advancing?

Stavric, S. G., Bonello, F., Bringhen, S., Boccadoro, M., & Larocca, A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1326814 · Cited by 11

EWSR1 overexpression is a pro-oncogenic event in multiple myeloma

Nishiyama, D., Chinen, Y., Isa, R., Fujibayashi, Y., Kuwahara‐Ota, S., Yamaguchi, J., Takimoto‐Shimomura, T., Matsumura‐Kimoto, Y., Tsukamoto, T., Shimura, Y., et al. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-03027-0 · Cited by 11

Smoldering multiple myeloma – Past, present, and future

Mann, H., Katiyar, V., Varga, C., & Comenzo, R. L. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100869 · Cited by 12

Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma

Zhang, L., Zhang, R., Wang, J., Chen, Y., Qiao, C., Shi, Q., Jin, Y., Shen, X., Li, J., & Chen, L. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01314-7 · Cited by 11

Defining the origin, evolution, and immune composition of SDH-deficient renal cell carcinoma

Neves, J. B., Roberts, K., Sivakumaran, S., Sheikh, S. E., Tran‐Dang, M., Horsfield, C. J., Mumtaz, F., Campbell, P. J., Stauss, H. J., Tran, M. G. B., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105389 · Cited by 11

Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma

Matera, A., Marella, A., Maeda, A., Vià, M. D., Lazzaroni, F., Fabris, S., Pioggia, S., Porretti, L., Colombo, F., Torricelli, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415691 · Cited by 11

High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics

Xia, Y., Shen, N., Zhang, R., Wu, Y., Shi, Q., Li, J., Chen, L., Xu, M., & Jin, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1083053 · Cited by 11

Bone marrow Ki‐67 index is of prognostic value in newly diagnosed multiple myeloma

Atrash, S., Robinson, M. M., Taneja, A., Paul, B. A., Cassetta, K., Ndiaye, A. P., Varga, C., Block, J. G., Lipford, E. H., Smith, E. T., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14016 · Cited by 11

DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification

Favasuli, V. K., Ronchetti, D., Silvestris, I., Puccio, N., Fabbiano, G., Traini, V., Todoerti, K., Erratico, S., Ciarrocchi, A., Fragliasso, V., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283274 · Cited by 11

BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma

Fang, J., & Zhou, F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05444-7 · Cited by 12

Myeloma Propagating Cells, Drug Resistance and Relapse

Karadimitris, A., Chaidos, A., Caputo, V. S., Goudevenou, K., Ponnusamy, K., & Xiao, X. (2015) · Stem Cells · doi:10.1002/stem.2199 · Cited by 11

Potential of oncolytic viruses in the treatment of multiple myeloma

Bartee, E. (2018) · Oncolytic Virotherapy · doi:10.2147/ov.s136644 · Cited by 11

Tracking myeloma tumor DNA in peripheral blood

Waldschmidt, J. M., Vijaykumar, T., Knoechel, B., & Lohr, J. G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101146 · Cited by 12

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma

Manzoni, M., Marchica, V., Storti, P., Ziccheddu, B., Sammarelli, G., Todaro, G., Pelizzoni, F., Salerio, S., Notarfranchi, L., Pompa, A., et al. (2020) · Cancers · doi:10.3390/cancers12051332 · Cited by 11

Growth Factor–like Gene Regulation Is Separable from Survival and Maturation in Antibody-Secreting Cells

Stephenson, S., Care, M. A., Fan, I., Zougman, A., Westhead, D. R., Doody, G. M., & Tooze, R. M. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801407 · Cited by 11

Postzygotic Somatic Mutations in the Human Brain Expand the Threshold-Liability Model of Schizophrenia

Singh, S. M., Castellani, C. A., & Hill, K. A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.587162 · Cited by 11

Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenström’s Macroglobulinemia—A Particularly Heterogeneous Lymphoma

García‐Sánz, R., & Jiménez, C. (2021) · Cancers · doi:10.3390/cancers13071541 · Cited by 11

Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma

Rana, P. S., Goparaju, K., & Driscoll, J. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1141851 · Cited by 10

Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients

Hu, Y., Chen, W., & Wang, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s216289 · Cited by 10

Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value

Li, J., Tan, H., Xu, T., Shi, H., & Liu, P. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04629-2 · Cited by 10

Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in Multiple Myeloma: Application Potential, Challenges, and Opportunities

Heestermans, R., Schots, R., Becker, A. D., & Riet, I. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105208 · Cited by 12

Exploring the Role of Clustered Mutations in Carcinogenesis and Their Potential Clinical Implications in Cancer

Li, Y., Zhu, R., Jin, J., Guo, H., Zhang, J., He, Z., Liang, T., & Guo, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126744 · Cited by 11

Concomitant MDS with isolated 5q deletion and MGUS : case report and review of molecular aspects

Nolte, F., Mossner, M., Jann, J.-C., Nowak, D., Boch, T., Müller, N., Hofmann, W., & Metzgeroth, G. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12827 · Cited by 10

Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic

Morgan, G. J., & Rasche, L. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1489718 · Cited by 10

Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma

Kumar, A., Adhikari, S., Kankainen, M., & Heckman, C. A. (2021) · Cancers · doi:10.3390/cancers13061212 · Cited by 10

Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision‐making

Clark, C. A., Cornell, R. F., Scott, E. C., Chung, J., & Costa, L. J. (2016) · American Journal of Hematology · doi:10.1002/ajh.24478 · Cited by 10

IQGAP1 Scaffold–MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal

Gocke, C. B., McMillan, R. H., Wang, Q., Begum, A., Penchev, V. R., Ali, S. A., Borrello, I., Huff, C. A., & Matsui, W. H. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0323 · Cited by 10

Safety issues and management of toxicities associated with new treatments for multiple myeloma

Brioli, A., Mügge, L., Hochhaus, A., & von Lilienfeld‐Toal, M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1284584 · Cited by 10

Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis

Ntanasis‐Stathopoulos, I., Gavriatopoulou, M., Terpos, E., Fotiou, D., Kastritis, E., & Dimopoulos, M. A. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.06.025 · Cited by 11

Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett’s Adenocarcinoma Cells

Pal, J., Nanjappa, P., Kumar, S., Shi, J., Buon, L., Munshi, N. C., & Shammas, M. A. (2017) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2017.06.687 · Cited by 10

Transient paraproteinemia after allogeneic hematopoietic stem cell transplantation is an underexplored phenomenon associated with graft versus host disease

Widmer, C. C., Balabanov, S., Schanz, U., & Theocharides, A. P. A. (2017) · Oncotarget · doi:10.18632/oncotarget.22462 · Cited by 9

Low‐depth sequencing for copy number abnormalities in multiple myeloma supersedes fluorescent in situ hybridization in scope and resolution

Elnenaei, M. O., Knopf, P., Cutler, S. D., Sinclair, K., Hassan, M. A. E., Greer, W. L., Goudie, M., Wagner, J., White, D. J., Couban, S., et al. (2019) · Clinical Genetics · doi:10.1111/cge.13561 · Cited by 9

Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones

Ndacayisaba, L. J., Rappard, K. E., Shishido, S. N., Velasco, C. R., Matsumoto, N., Navarez, R., Tang, G., Lin, P., Setayesh, S. M., Naghdloo, A., et al. (2022) · Current Oncology · doi:10.3390/curroncol29050242 · Cited by 10

Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study

Heestermans, R., Brouwer, W. D., Maes, K., Broek, I. V., Vaeyens, F., Olsen, C., Caljon, B., Becker, A. D., Bakkus, M. H. C., Schots, R., et al. (2022) · Cancers · doi:10.3390/cancers14194901 · Cited by 10

Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma

Baughn, L. B., Jessen, E., Sharma, N., Tang, H., Smadbeck, J. B., Long, M. D., Pearce, K. E., Smith, M., Dasari, S., Sachs, Z., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00851-5 · Cited by 9

Impact of Clonal Heterogeneity in Multiple Myeloma

Schinke, C., Rasche, L., Raab, M. S., & Weinhold, N. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.012 · Cited by 9

Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker

Ryu, D., Kim, H., Joung, J., Lee, H., Bae, J. S., Kim, H., Kim, H., Park, W., & Kım, K. (2016) · Oncotarget · doi:10.18632/oncotarget.9478 · Cited by 9

Detection of copy number alterations in cell-free tumor DNA from plasma

Østrup, O., Ahlborn, L. B., Lassen, U., Mau‐Sørensen, M., & Nielsen, F. C. (2017) · BBA Clinical · doi:10.1016/j.bbacli.2017.03.006 · Cited by 9

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients

Ely, S. A., Forsberg, P. A., Ouansafi, I., Rossi, A., Modin, A., Pearse, R. N., Pekle, K. A., Perry, A., Coleman, M., Jayabalan, D. S., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.09.010 · Cited by 9

Array comparative genomic hybridization of 18 pancreatic ductal adenocarcinomas and their autologous metastases

Rausch, V., Krieg, A. H., Camps, J., Behrens, B., Beier, M., Wangsa, D., Heselmeyer‐Haddad, K., Baldus, S. E., Knoefel, W. T., Ried, T., et al. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2886-0 · Cited by 9

Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review

Nishihori, T., & Shain, K. H. (2017) · International Journal of Genomics · doi:10.1155/2017/6934183 · Cited by 9

Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1

Spaan, I., van de Stolpe, A., Raymakers, R. A. P., & Peperzak, V. (2021) · Cancers · doi:10.3390/cancers13184668 · Cited by 9

Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing

Salomon‐Perzyński, A., Barankiewicz, J., Machnicki, M. M., Misiewicz-Krzemińska, I., Pawlak, M., Radomska, S., Krzywdzińska, A., Bluszcz, A., Stawiński, P., Rydzanicz, M., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071674 · Cited by 9

Clinical and genomic characterization of mutational signatures across human cancers

Liao, J., Bai, J., Pan, T., Zou, H., Gao, Y., Guo, J., Xu, Q., Xu, J., Li, Y., & Li, X. (2022) · International Journal of Cancer · doi:10.1002/ijc.34402 · Cited by 10

Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis

Kim, S. J., Shin, H., Lee, H., Kim, N. K. D., Yun, J. W., Hwang, J. H., Kım, K., & Park, W. (2016) · Oncotarget · doi:10.18632/oncotarget.12029 · Cited by 9

Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach

González‐Calle, V., Keane, N., Braggio, E., & Fonseca, R. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.021 · Cited by 9

Potential Clinical Application of Genomics in Multiple Myeloma

Soekojo, C. Y., Mel, S. D., Ooi, M. G. M., Yan, B., & Chng, W. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061721 · Cited by 9

A statistical approach for tracking clonal dynamics in cancer using longitudinal next-generation sequencing data

Vavoulis, D. V., Cutts, A., Taylor, J. C., & Schuh, A. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa672 · Cited by 9

Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

Ninkovic, S., & Quach, H. (2020) · Cancers · doi:10.3390/cancers12113488 · Cited by 9

New regimens and directions in the management of newly diagnosed multiple myeloma

Bal, S., Giri, S., Godby, K. N., & Costa, L. J. (2021) · American Journal of Hematology · doi:10.1002/ajh.26080 · Cited by 9

Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma

Lee, N., Kim, S., Lee, Y., Jeong, D., Yun, J., Ryu, S., Yoon, S., Ahn, Y., Hwang, S. M., & Lee, D. S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0246322 · Cited by 10

The molecular biology of multiple myeloma

Chng, W. J., & Bergsagel, P. L. (2019) · Wiley eBooks · doi:10.1002/9781119252863.ch10 · Cited by 9

Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/β‑catenin signaling pathway

Dai, Y., Guo, X., & Yang, C. (2020) · Oncology Letters · doi:10.3892/ol.2020.11678 · Cited by 8

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Yee, A. J., & Raje, N. S. (2016) · Hematology · doi:10.1182/asheducation-2016.1.495 · Cited by 8

Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies

Al‐Anazi, K. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.79999 · Cited by 8

Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions

Chojnacka, M., Diamond, B. T., Landgren, O., & Maura, F. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.006 · Cited by 8

Identification of mutation gene prognostic biomarker in multiple myeloma through gene panel exome sequencing and transcriptome analysis in Chinese population

Xie, C., Zhong, L., Luo, J., Luo, J., Wu, Y., Zheng, S., Jiang, L., Zhang, J., & Shi, Y. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107224 · Cited by 8

AmplificationTimeR: an R package for timing sequential amplification events

Jakobsdottir, G. M., Dentro, S. C., Bristow, R. G., & Wedge, D. C. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae281 · Cited by 8

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+

Sklavenitis‐Pistofidis, R., Lightbody, E. D., Reidy, M., Tsuji, J., Alberge, J.-B., Aranha, M. P., Heilpern-Mallory, D., Roweth, H. G., Huynh, D., Chong, S. J. F., et al. (2025) · Blood · doi:10.1182/blood.2024025102 · Cited by 8

Protocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma

Barrio, S., Vià, M. D., Bruins, L. A., Stühmer, T., Steinbrunn, T., Bittrich, M., Einsele, H., Stewart, A. K., Braggio, E., & Kortüm, K. M. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7865-6_8 · Cited by 8

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma

Vlummens, P., Veirman, K. D., Menu, E., Bruyne, E. D., Offner, F. C., Vanderkerken, K., & Maes, K. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00740 · Cited by 9

P-047: Clonal evolution in multiple myeloma evaluated by Whole Exome Sequencing

Gupta, R., Kaur, G., Farswan, A., Jena, L., Gupta, A., Rani, L., Kumar, L., & Sharma, A. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(21)02181-9

Whole Exome Sequencing Of Multiple Myeloma Reveals An Heterogeneous Clonal Architecture and Genomic Evolution

Bolli, N., Avet‐Loiseau, H., Wedge, D. C., Loo, P. V., Alexandrov, L. B., Martin, S., Dawson, K. J., Iorio, F., Nik‐Zainal, S., Bignell, G. R., et al. (2013) · Blood · doi:10.1182/blood.v122.21.399.399 · Cited by 1

Genomic Evolution and Clinical Correlates

Campbell, P. J. (2013) · Blood · doi:10.1182/blood.v122.21.sci-15.sci-15

Multiple Myeloma Sequencing Reveals Subclonality and Timing of Genetic Alterations

Lohr, J. G., Stojanov, P., Lawrence, M. S., Auclair, D., Carter, S. L., Sougnez, C. L., Gould, J., Cruz‐Gordillo, P., Chapman, M. A., Getz, G. A., et al. (2011) · Blood · doi:10.1182/blood.v118.21.2897.2897

Genomic complexity of multiple myeloma and its clinical implications

Manier, S., Salem, K. Z., Park, J., Landau, D. A., Getz, G. A., & Ghobrial, I. M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.122 · Cited by 579